{"analyses":[{"ciLowerLimit":"0.6989","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.1182","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.3038","paramType":"Odds Ratio (OR)","paramValue":"0.8840","statisticalMethod":"Chi-squared","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"397"},{"groupId":"OG001","value":"649"}]}],"title":"Primary (initiated in cycle1)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"164"},{"groupId":"OG001","value":"237"}]}],"title":"Secondary (initiated in cycle2 or later)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"561"},{"groupId":"OG001","value":"886"}],"units":"Participants"}],"description":"Objective 2: To describe EP2006 primary or secondary prophylaxis patterns for FN over up to 6 cycles of chemotherapy, with or without prior, concurrent, or later radiotherapy or surgery.","groups":[{"description":"Male cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.","id":"OG000","title":"EP2006: Male"},{"description":"Female cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.","id":"OG001","title":"EP2006: Female"}],"paramType":"NUMBER","populationDescription":"Evaluable sample by gender","reportingStatus":"POSTED","timeFrame":"All cycles. Patients were evaluated at the enrollment cycle and then re-evaluated at each cycle for a maximum total of 6 cycles; however, the scheduling of these evaluations was left to the discretion of the physician, mean duration of study for 105 days","title":"Type of EP2006 Prophylaxis by Gender","type":"PRIMARY","unitOfMeasure":"participants"}